PTEN and cervical cancer: However, the secondary analysis results of the CLAP trial suggest that PTEN alterations were associated with improved outcomes in patients with cervical cancer treated with PD-1 inhibitor combination therapy, conferred longer PFS (p = 0.05) and trended towards increased OS (p = 0.08) [7].